• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非小细胞肺癌患者脑转移高危组的识别。

Identification of a high-risk group for brain metastases in non-small cell lung cancer patients.

作者信息

Cacho-Díaz Bernardo, Cuapaténcatl Laura Denisse, Rodríguez Jose Antonio, Garcilazo-Reyes Ytel Jazmin, Reynoso-Noverón Nancy, Arrieta Oscar

机构信息

Neuro Oncology Unit, National Cancer Institute, San Fernando 22, Tlalpan, 14080, Mexico City, ZC, Mexico.

Research Department, National Cancer Institute, Mexico City, Mexico.

出版信息

J Neurooncol. 2021 Oct;155(1):101-106. doi: 10.1007/s11060-021-03849-w. Epub 2021 Sep 21.

DOI:10.1007/s11060-021-03849-w
PMID:34546499
Abstract

PURPOSE

Identification of a high-risk group of brain metastases (BM) in patients with non-small cell lung cancer (NSCLC) could lead to early interventions and probably better prognosis. The objective of the study was to identify this group by generating a multivariable model with recognized and accessible risk factors.

METHODS

A retrospective cohort from patients seen at a single center during 2010-2020, was divided into a training (TD) and validation (VD) datasets, associations with BM were measured in the TD with logit, variables significantly associated were used to generate a multivariate model. Model´s performance was measured with the AUC/C-statistic, Akaike information criterion, and Brier score.

RESULTS

From 570 patients with NSCLC who met the strict eligibility criteria a TD and VD were randomly assembled, no significant differences were found amid both datasets. Variables associated with BM in the multivariate logit analyses were age [P 0.001, OR 0.96 (95% CI 0.93-0.98)]; mutational status positive [P 0.027, OR 1.96 (95% CI 1.07-3.56); and carcinoembryonic antigen levels [P 0.016, OR 1.001 (95% CI 1.000-1.003). BM were diagnosed in 24% of the whole cohort. Stratification into a high-risk group after simplification of the model, displayed a frequency of BM of 63% (P < 0.001).

CONCLUSION

A multivariate model comprising age, carcinoembryonic antigen levels, and mutation status allowed the identification of a truly high-risk group of BM in NSCLC patients.

摘要

目的

识别非小细胞肺癌(NSCLC)患者中脑转移(BM)的高危组,这可能会带来早期干预并可能改善预后。本研究的目的是通过构建一个包含公认且易于获取的风险因素的多变量模型来识别该组患者。

方法

对2010年至2020年在单一中心就诊的患者进行回顾性队列研究,将其分为训练(TD)和验证(VD)数据集,在TD中用逻辑回归测量与BM的关联,使用与BM显著相关的变量生成多变量模型。用AUC/C统计量、赤池信息准则和布里尔评分来衡量模型的性能。

结果

从570例符合严格纳入标准的NSCLC患者中随机组建了TD和VD,两个数据集之间未发现显著差异。多变量逻辑回归分析中与BM相关的变量有年龄[P = 0.001,OR = 0.96(95%CI 0.93 - 0.98)];突变状态为阳性[P = 0.027,OR = 1.96(95%CI 1.07 - 3.56)];以及癌胚抗原水平[P = 0.016,OR = 1.001(95%CI 1.000 - 1.003)]。整个队列中有24%被诊断为BM。模型简化后分层为高危组,BM的发生率为63%(P < 0.001)。

结论

一个包含年龄、癌胚抗原水平和突变状态的多变量模型能够识别NSCLC患者中真正的BM高危组。

相似文献

1
Identification of a high-risk group for brain metastases in non-small cell lung cancer patients.非小细胞肺癌患者脑转移高危组的识别。
J Neurooncol. 2021 Oct;155(1):101-106. doi: 10.1007/s11060-021-03849-w. Epub 2021 Sep 21.
2
Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy.伴有EGFR突变的非小细胞肺癌脑转移的预后因素:颅外疾病稳定及厄洛替尼治疗的影响
Med Oncol. 2014 Oct;31(10):228. doi: 10.1007/s12032-014-0228-9. Epub 2014 Sep 11.
3
Association of neurologic manifestations and CEA levels with the diagnosis of brain metastases in lung cancer patients.神经系统表现和 CEA 水平与肺癌脑转移患者诊断的相关性。
Clin Transl Oncol. 2019 Nov;21(11):1538-1542. doi: 10.1007/s12094-019-02086-y. Epub 2019 Mar 22.
4
Identification of subgroup patients with stage IIIB/IV non-small cell lung cancer at higher risk for brain metastases.识别 IIIB/IV 期非小细胞肺癌亚组患者中脑转移风险较高的患者。
Lung Cancer. 2013 Nov;82(2):319-23. doi: 10.1016/j.lungcan.2013.08.004. Epub 2013 Aug 13.
5
Risk factors for brain metastases from non-small-cell lung cancer: A protocol for observational study.非小细胞肺癌脑转移的风险因素:一项观察性研究方案。
Medicine (Baltimore). 2021 Mar 5;100(9):e24724. doi: 10.1097/MD.0000000000024724.
6
Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan.日本真实世界研究:初诊非小细胞肺癌脑转移患者的管理与结局。
Oncology. 2020;98(7):460-467. doi: 10.1159/000506368. Epub 2020 Mar 27.
7
Down-regulated microRNA-375 expression as a predictive biomarker in non-small cell lung cancer brain metastasis and its prognostic significance.下调的微小RNA-375表达作为非小细胞肺癌脑转移的预测生物标志物及其预后意义。
Pathol Res Pract. 2017 Aug;213(8):882-888. doi: 10.1016/j.prp.2017.06.012. Epub 2017 Jul 1.
8
Isolated Brain Metastases as the First Relapse After the Curative Surgical Resection in Non-Small-Cell Lung Cancer Patients With an EGFR Mutation.EGFR 突变非小细胞肺癌患者根治性手术后孤立性脑转移作为首次复发。
Clin Lung Cancer. 2018 Jan;19(1):e29-e36. doi: 10.1016/j.cllc.2017.05.017. Epub 2017 Jun 1.
9
Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma.局部非小细胞肺癌脑转移预测因素的多变量分析。
Lung Cancer. 2004 Sep;45(3):317-23. doi: 10.1016/j.lungcan.2004.01.025.
10
Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.表皮生长因子受体突变和间变性淋巴瘤激酶重排对非小细胞肺癌脑转移患者结局的影响。
Neuro Oncol. 2020 Feb 20;22(2):267-277. doi: 10.1093/neuonc/noz155.

引用本文的文献

1
Antiplatelet Therapy Mitigates Brain Metastasis Risk in Non-Small Cell Lung Cancer: Insights from a Comprehensive Retrospective Study.抗血小板治疗可降低非小细胞肺癌脑转移风险:一项全面回顾性研究的见解
Cancers (Basel). 2025 Jun 20;17(13):2059. doi: 10.3390/cancers17132059.
2
Perilesional edema diameter associated with brain metastases as a predictive factor of response to radiotherapy in non-small cell lung cancer.与脑转移相关的瘤周水肿直径作为非小细胞肺癌放疗反应的预测因素
Front Oncol. 2023 Oct 17;13:1251620. doi: 10.3389/fonc.2023.1251620. eCollection 2023.
3
Prediction of adenocarcinoma and squamous carcinoma based on CT perfusion parameters of brain metastases from lung cancer: a pilot study.
基于肺癌脑转移瘤CT灌注参数预测腺癌和鳞癌:一项初步研究。
Front Oncol. 2023 Sep 20;13:1225170. doi: 10.3389/fonc.2023.1225170. eCollection 2023.
4
Individual risk and prognostic value prediction by machine learning for distant metastasis in pulmonary sarcomatoid carcinoma: a large cohort study based on the SEER database and the Chinese population.基于SEER数据库和中国人群的大样本队列研究:机器学习预测肺肉瘤样癌远处转移的个体风险及预后价值
Front Oncol. 2023 Jun 26;13:1105224. doi: 10.3389/fonc.2023.1105224. eCollection 2023.
5
Brain parenchymal and leptomeningeal metastasis in non-small cell lung cancer.非小细胞肺癌的脑实质和软脑膜转移。
Sci Rep. 2022 Dec 26;12(1):22372. doi: 10.1038/s41598-022-26131-z.
6
Machine Learning for the Prediction of Synchronous Organ-Specific Metastasis in Patients With Lung Cancer.用于预测肺癌患者同步器官特异性转移的机器学习
Front Oncol. 2022 May 13;12:817372. doi: 10.3389/fonc.2022.817372. eCollection 2022.
7
The clinical outcome and risk factors analysis of immune checkpoint inhibitor-based treatment in lung adenocarcinoma patients with brain metastases.肺腺癌脑转移患者基于免疫检查点抑制剂治疗的临床结局及危险因素分析
Transl Lung Cancer Res. 2022 Apr;11(4):656-669. doi: 10.21037/tlcr-22-260.